Drug Trial Radar · NCT04307576
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,430
Planned (sponsor's estimate)
Start
Jul 13, 2020
Primary completion
Jun 2033
Study completion Jun 2033
Sponsor
- Lead sponsor
- Mats HeymanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Swedish Research Council; The Swedish Childhood Cancer Foundation; Pfizer; Servier; NordForsk; Aamu Pediatric Cancer Foundation; German Society for Pediatric Oncology and Hematology GPOH gGmbH; Clinical Trial Center North (CTC North GmbH & Co. KG); Belgium Health Care Knowledge Centre; Karolinska Institutet; Cancer Research UK; Fundação Rui Osório de Castro; Acreditar - Associação de Pais e Amigos das Crianças com Cancro; Grupo Português De Leucemias Pediátricas; Amgen; Nova Laboratories Limited; Danish Child Cancer Foundation; Danish Cancer Society; The Novo Nordic Foundation; Assistance Publique - Hôpitaux de Paris; Direction Générale de l'Offre de Soins; Swedish Cancer Society
- First posted
- Mar 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
Conditions
- Leukemia, Acute Lymphoblastic
Interventions
Omitted DoxorubicinDrug
Omission of IV Doxorubicin
Omitted Vincristine+Dexamethasone pulsesDrug
Omission of Vincristine+Dexamethasone pulses
Inotuzumab Ozogamicin+Standard Maintenance TherapyDrug
Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
ImatinibDrug
p.o. Imatinib
6-tioguanine+Standard Maintenance TherapyDrug
Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
BlinatumomabDrug
IV Blinatumomab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS) for the whole protocolTime frame: 5 year estimates from the time of diagnosis will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up.
- Event-free survival (EFS) for the TKI interventionTime frame: From the start of TKI (day 15 or day 30), 5 year estimates will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up for all interventions except Inotuzumab-randomisation (minimum 2-year follow-up).
- Disease-free survival (DFS) R1 + R2Time frame: 5 and 8 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up.
- Disease-free survival (DFS) R3Time frame: 5 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 2-year follow-up
- MRD response after 1 cycle of BlinatumomabTime frame: End of first Blinatumomab infusion +/- 1 week
Locations
137 sites in 15 countries. Site status is shown where the registry gives one.
L'hôpital Universitaire des enfants Reine Fabiola (Huderf)
Brussels, Belgium · Recruiting
Cliniques Universitaires Saint-Luc (UCL)
Brussels, Belgium · Recruiting
University Hospital Antwerp
Edegem, Belgium · Recruiting
University Hospital Ghent
Ghent, Belgium · Recruiting
University Hospital Leuven, Dept of Paediatrics
Leuven, Belgium · Recruiting
CHC MontLégia, Boulevard Patience et Beaujonc 2
Liège, Belgium · Recruiting
CHR de la Citadelle
Liège, Belgium · Recruiting
Aalborg University Hospital, Dept of Paediatrics
Aalborg, Denmark · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Aarhus University Hospital, Child and Adolescent Health
Aarhus, Denmark · Recruiting
Rigshospitalet, Dept of Haematology
Copenhagen, Denmark · Recruiting
Rigshospitalet, Dept of Paediatrics
Copenhagen, Denmark · Recruiting
Odense University Hospital, Dept of Paediatrics
Odense, Denmark · Recruiting
North Estonia Medical Centre, Dept of Haematology
Tallinn, Estonia · Recruiting
Tallinn Children´s Hospital, Dept of Paediatrics
Tallinn, Estonia · Recruiting
Tartu University Hospital
Tartu, Estonia · Recruiting
Helsinki University Hospital, Dept of Haematology
Helsinki, Finland · Recruiting
Helsinki University Hospital, Dept of Paediatrics
Helsinki, Finland · Recruiting
Kuopio University Hospital, Dept of Haematology
Kuopio, Finland · Recruiting
Kuopio University Hospital, Dept of Paediatrics
Kuopio, Finland · Recruiting
Oulu University Hospital, Dept of Haematology, Dept of Medicine
Oulu, Finland · Recruiting
Oulu University Hospital, Dept of Paediatrics
Oulu, Finland · Recruiting
Tampere University Hospital, Dept of Haematology
Tampere, Finland · Recruiting
Tampere University Hospital, Dept of Paediatrics
Tampere, Finland · Recruiting
Turku University Hospital, Clinical Haematology and Stem Cell Transplantation Unit
Turku, Finland · Recruiting
Turku University Hospital, Dept of Paediatrics
Turku, Finland · Recruiting
CHU Amiens Groupe Hospitalier Sud
Amiens, France · Recruiting
CHU Angers
Angers, France · Recruiting
CHRU Besançon
Besançon, France · Recruiting
CHU Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, France · Recruiting
CHRU Brest - Morvan
Brest, France · Recruiting
Centre Hospitalier Universitaire Caen
Caen, France · Recruiting
CHU Clermont-Ferrand
Clermont-Ferrand, France · Recruiting
CHU Dijon Hôpital François Mitterrand
Dijon, France · Recruiting
CHU de Grenoble site Nord - Hôpital Albert Michallon
Grenoble, France · Recruiting
CHRU de Lille - Hôpital Jeanne de Flandre
Lille, France · Recruiting
Hôpital de la mère et de l'enfant
Limoges, France · Recruiting
CHU de Lyon HCL - GH Est-Institut d'hématologie et d'oncologie pédiatrique IHOP
Lyon, France · Recruiting
CHU de Marseille - Hôpital de la Timone
Marseille, France · Recruiting
CHU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France · Recruiting
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.